Broad-spectrum antiviral capsules

Triazavirin (Riamilovir)

triazaverin.png

Pharmachal has secured regional distribution for the novel, broad-spectrum antiviral capsule Triazavirin (Riamilovir), which has indications registered for antiviral activity against viruses including Influenza SARS A & B, Upper Respiratory Track Viral Infections, and has shown clinically to be effective against SARS-CoV-2, the virus that causes COVID-19.

2020 Clinical Testing in Russia and China, and observational reports from Kenya, found that Triazavirin delivered significant antiviral activity against SARS-CoV-2. Medical clinics in these countries have subsequently provided the drug to infected patients of COVID-19 under special access programs and production has increased to meet growing demand.

Pharmachal has appointed a regulatory consultant to prepare the documentation for registration of the drug as an antiviral SARS A & B flu drug. Management is communicating with Government health officials in institutions and hospitals to provide the drug under the TGA SAS A & B (Special Access) programme for patients confirmed to have the DELTA variant of COVID-19.

Pharmachal also plans to reformulate Triazavirin into a nasal spray utilizing the company’s proprietary nano drug delivery technology.